Anixa Secures Patent for Breast Cancer Vaccine in South Korea
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 41 minutes ago
0mins
Source: PRnewswire
- Patent Protection Extended: Anixa has secured a composition-of-matter patent for its breast cancer vaccine from the Korean Intellectual Property Office, valid until 2040, which solidifies its global intellectual property strategy and reinforces its leadership in cancer immunotherapy.
- Market Demand Response: With the rapid increase in breast cancer incidence rates in South Korea, particularly among younger patients, the patent enables Anixa to better address the urgent market need for preventive vaccines, facilitating future regulatory approvals and commercialization opportunities.
- Clinical Trial Success: In a Phase 1 clinical trial conducted at Cleveland Clinic, Anixa's vaccine generated immune responses in 74% of participants and demonstrated good safety, laying a solid foundation for continued clinical development and potentially transforming breast cancer prevention strategies.
- Global Strategic Positioning: By strengthening its global patent estate, Anixa is establishing a foundation for future international development and commercialization strategies, showcasing its innovative capabilities in cancer prevention and potentially becoming the first preventive vaccine targeting breast cancer, which could have transformative implications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIX
Wall Street analysts forecast ANIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.790
Low
10.00
Averages
10.00
High
10.00
Current: 2.790
Low
10.00
Averages
10.00
High
10.00
No data
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anixa Secures Patent for Breast Cancer Vaccine in South Korea
- Patent Protection Extended: Anixa has secured a composition-of-matter patent for its breast cancer vaccine from the Korean Intellectual Property Office, valid until 2040, which solidifies its global intellectual property strategy and reinforces its leadership in cancer immunotherapy.
- Market Demand Response: With the rapid increase in breast cancer incidence rates in South Korea, particularly among younger patients, the patent enables Anixa to better address the urgent market need for preventive vaccines, facilitating future regulatory approvals and commercialization opportunities.
- Clinical Trial Success: In a Phase 1 clinical trial conducted at Cleveland Clinic, Anixa's vaccine generated immune responses in 74% of participants and demonstrated good safety, laying a solid foundation for continued clinical development and potentially transforming breast cancer prevention strategies.
- Global Strategic Positioning: By strengthening its global patent estate, Anixa is establishing a foundation for future international development and commercialization strategies, showcasing its innovative capabilities in cancer prevention and potentially becoming the first preventive vaccine targeting breast cancer, which could have transformative implications.
See More
Anixa Biosciences Advances Cancer Immunotherapy Programs
- Breast Cancer Vaccine Progress: Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, completed its Phase 1 trial with all major endpoints met and 74% of participants showing protocol-defined immune responses, indicating potential efficacy and safety that could pave the way for new cancer prevention strategies.
- Ovarian Cancer CAR-T Therapy: Anixa's ovarian cancer CAR-T therapy, lira-cel, has shown positive survival observations in an ongoing Phase 1 trial at Moffitt Cancer Center, with multiple patients living over a year post-treatment, suggesting significant potential for improving patient survival rates and offering new hope for ovarian cancer patients.
- Strengthened Clinical Collaborations: Anixa showcased its clinical advancements at the Frontiers in Cancer Immunotherapy symposium, emphasizing partnerships with Cleveland Clinic and Moffitt Cancer Center, which not only enhances the company's industry reputation but may also attract further investment and collaboration opportunities.
- Innovative Business Model: By partnering with leading research institutions, Anixa continuously explores emerging technologies to advance its cancer vaccines and CAR-T therapies, demonstrating a unique business model that could provide the company with a long-term competitive advantage in the cancer treatment market.
See More
Anixa Biosciences Advances Cancer Immunotherapy Programs
- Breast Cancer Vaccine Success: Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, completed its Phase 1 trial with all major endpoints met and 74% of participants showing protocol-defined immune responses, indicating its potential effectiveness and safety for future cancer prevention.
- Ovarian Cancer CAR-T Progress: The ovarian cancer CAR-T therapy, lira-cel, is undergoing a Phase 1 trial in collaboration with Moffitt Cancer Center, with preliminary data showing multiple patients surviving over a year post-treatment, suggesting significant survival benefits that could transform ovarian cancer treatment.
- Strengthened Clinical Collaborations: Anixa showcased its clinical advancements at the New York Academy of Sciences' symposium, emphasizing partnerships with Cleveland Clinic and Moffitt Cancer Center, which not only enhances the company's industry reputation but may also attract further investment and collaboration opportunities.
- Innovative Business Model: By partnering with world-renowned research institutions, Anixa continuously develops novel cancer vaccines focusing on immunizing against
See More
Anixa Biosciences Highlights Clinical Progress at Cancer Immunotherapy Symposium
- Clinical Trial Progress: Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival observations in an ongoing Phase 1 clinical trial, with a presentation scheduled at the Frontiers in Cancer Immunotherapy symposium on June 22-23, 2026, which may further validate its therapeutic potential.
- Breast Cancer Vaccine Results: Anixa's breast cancer vaccine has met all major primary endpoints in its Phase 1 clinical trial, with 74% of participants generating protocol-defined immune responses, demonstrating the vaccine's safety and tolerability, thus laying a foundation for future clinical applications.
- Strengthened Collaborative Network: Anixa's partnerships with leading research institutions like Moffitt Cancer Center and Cleveland Clinic enhance the strength of its clinical programs, showcasing the company's innovative capabilities and competitive edge in cancer treatment.
- Increased Industry Influence: Anixa's CEO highlighted that the symposium presents a crucial opportunity to showcase the progress of its clinical pipeline, emphasizing the company's strategic positioning in cancer treatment and prevention, which could attract more investor interest.
See More
Anixa Secures Canadian Patent for Ovarian Cancer Vaccine
- Patent Approval: Anixa Biosciences announced the issuance of a Notice of Allowance from the Canadian Intellectual Property Office for its ovarian cancer vaccine technology, enhancing its international patent protection and supporting the novelty of its AMHR2-targeted immunoprevention approach.
- Collaborative Development: The vaccine technology is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, aiming to provide prevention and treatment options for high-risk populations, particularly those with BRCA mutations or a family history of ovarian cancer, highlighting its strategic importance in cancer prevention.
- International Expansion: This patent allowance not only complements Anixa's existing patent protection in the U.S. but also establishes a broader international intellectual property foundation for its cancer vaccine technologies, enhancing the company's competitiveness in the global market.
- Clinical Progress: Anixa's breast cancer vaccine has completed a Phase 1 clinical trial with all primary endpoints met, indicating ongoing innovation and development potential in cancer immunotherapy, further solidifying its position in the biotechnology industry.
See More
Anixa Biosciences Reports Positive Survival Data from Lira-cel Trial
- Extended Survival Rates: Anixa's lira-cel clinical trial has shown that several patients have survived significantly beyond the expected median survival, with one patient living for 28 months, indicating the therapy's potential to transform treatment outcomes for recurrent ovarian cancer patients.
- Clinical Trial Updates: Data presented on May 7, 2026, at the ISCT Annual Meeting highlighted lira-cel's favorable safety profile, with no dose-limiting toxicities observed, supporting ongoing dose escalation and clinical evaluation efforts.
- Optimized Treatment Protocol: Anixa plans to evaluate a dose approximately three times higher in the next cohort, incorporating lymphodepletion with cyclophosphamide and fludarabine, aiming to create a more favorable environment for CAR-T cell expansion and persistence, thereby enhancing therapeutic efficacy.
- Unique Target Advantage: Lira-cel targets the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells, representing a novel CAR-T target that may provide new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's competitive position in the biotechnology sector.
See More
Anixa Secures Patent for Breast Cancer Vaccine in South Korea
- Patent Protection Extended: Anixa has secured a composition-of-matter patent for its breast cancer vaccine from the Korean Intellectual Property Office, valid until 2040, which solidifies its global intellectual property strategy and reinforces its leadership in cancer immunotherapy.
- Market Demand Response: With the rapid increase in breast cancer incidence rates in South Korea, particularly among younger patients, the patent enables Anixa to better address the urgent market need for preventive vaccines, facilitating future regulatory approvals and commercialization opportunities.
- Clinical Trial Success: In a Phase 1 clinical trial conducted at Cleveland Clinic, Anixa's vaccine generated immune responses in 74% of participants and demonstrated good safety, laying a solid foundation for continued clinical development and potentially transforming breast cancer prevention strategies.
- Global Strategic Positioning: By strengthening its global patent estate, Anixa is establishing a foundation for future international development and commercialization strategies, showcasing its innovative capabilities in cancer prevention and potentially becoming the first preventive vaccine targeting breast cancer, which could have transformative implications.
See More
Anixa Biosciences Advances Cancer Immunotherapy Programs
- Breast Cancer Vaccine Progress: Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, completed its Phase 1 trial with all major endpoints met and 74% of participants showing protocol-defined immune responses, indicating potential efficacy and safety that could pave the way for new cancer prevention strategies.
- Ovarian Cancer CAR-T Therapy: Anixa's ovarian cancer CAR-T therapy, lira-cel, has shown positive survival observations in an ongoing Phase 1 trial at Moffitt Cancer Center, with multiple patients living over a year post-treatment, suggesting significant potential for improving patient survival rates and offering new hope for ovarian cancer patients.
- Strengthened Clinical Collaborations: Anixa showcased its clinical advancements at the Frontiers in Cancer Immunotherapy symposium, emphasizing partnerships with Cleveland Clinic and Moffitt Cancer Center, which not only enhances the company's industry reputation but may also attract further investment and collaboration opportunities.
- Innovative Business Model: By partnering with leading research institutions, Anixa continuously explores emerging technologies to advance its cancer vaccines and CAR-T therapies, demonstrating a unique business model that could provide the company with a long-term competitive advantage in the cancer treatment market.
See More
Anixa Biosciences Advances Cancer Immunotherapy Programs
- Breast Cancer Vaccine Success: Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, completed its Phase 1 trial with all major endpoints met and 74% of participants showing protocol-defined immune responses, indicating its potential effectiveness and safety for future cancer prevention.
- Ovarian Cancer CAR-T Progress: The ovarian cancer CAR-T therapy, lira-cel, is undergoing a Phase 1 trial in collaboration with Moffitt Cancer Center, with preliminary data showing multiple patients surviving over a year post-treatment, suggesting significant survival benefits that could transform ovarian cancer treatment.
- Strengthened Clinical Collaborations: Anixa showcased its clinical advancements at the New York Academy of Sciences' symposium, emphasizing partnerships with Cleveland Clinic and Moffitt Cancer Center, which not only enhances the company's industry reputation but may also attract further investment and collaboration opportunities.
- Innovative Business Model: By partnering with world-renowned research institutions, Anixa continuously develops novel cancer vaccines focusing on immunizing against
See More
Anixa Biosciences Highlights Clinical Progress at Cancer Immunotherapy Symposium
- Clinical Trial Progress: Anixa's ovarian cancer CAR-T therapy, lira-cel, is showing positive survival observations in an ongoing Phase 1 clinical trial, with a presentation scheduled at the Frontiers in Cancer Immunotherapy symposium on June 22-23, 2026, which may further validate its therapeutic potential.
- Breast Cancer Vaccine Results: Anixa's breast cancer vaccine has met all major primary endpoints in its Phase 1 clinical trial, with 74% of participants generating protocol-defined immune responses, demonstrating the vaccine's safety and tolerability, thus laying a foundation for future clinical applications.
- Strengthened Collaborative Network: Anixa's partnerships with leading research institutions like Moffitt Cancer Center and Cleveland Clinic enhance the strength of its clinical programs, showcasing the company's innovative capabilities and competitive edge in cancer treatment.
- Increased Industry Influence: Anixa's CEO highlighted that the symposium presents a crucial opportunity to showcase the progress of its clinical pipeline, emphasizing the company's strategic positioning in cancer treatment and prevention, which could attract more investor interest.
See More
Anixa Secures Canadian Patent for Ovarian Cancer Vaccine
- Patent Approval: Anixa Biosciences announced the issuance of a Notice of Allowance from the Canadian Intellectual Property Office for its ovarian cancer vaccine technology, enhancing its international patent protection and supporting the novelty of its AMHR2-targeted immunoprevention approach.
- Collaborative Development: The vaccine technology is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, aiming to provide prevention and treatment options for high-risk populations, particularly those with BRCA mutations or a family history of ovarian cancer, highlighting its strategic importance in cancer prevention.
- International Expansion: This patent allowance not only complements Anixa's existing patent protection in the U.S. but also establishes a broader international intellectual property foundation for its cancer vaccine technologies, enhancing the company's competitiveness in the global market.
- Clinical Progress: Anixa's breast cancer vaccine has completed a Phase 1 clinical trial with all primary endpoints met, indicating ongoing innovation and development potential in cancer immunotherapy, further solidifying its position in the biotechnology industry.
See More
Anixa Biosciences Reports Positive Survival Data from Lira-cel Trial
- Extended Survival Rates: Anixa's lira-cel clinical trial has shown that several patients have survived significantly beyond the expected median survival, with one patient living for 28 months, indicating the therapy's potential to transform treatment outcomes for recurrent ovarian cancer patients.
- Clinical Trial Updates: Data presented on May 7, 2026, at the ISCT Annual Meeting highlighted lira-cel's favorable safety profile, with no dose-limiting toxicities observed, supporting ongoing dose escalation and clinical evaluation efforts.
- Optimized Treatment Protocol: Anixa plans to evaluate a dose approximately three times higher in the next cohort, incorporating lymphodepletion with cyclophosphamide and fludarabine, aiming to create a more favorable environment for CAR-T cell expansion and persistence, thereby enhancing therapeutic efficacy.
- Unique Target Advantage: Lira-cel targets the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells, representing a novel CAR-T target that may provide new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's competitive position in the biotechnology sector.
See More
